30+ Product Approvals and Counting

Supporting over 300+ clinical trials in Ophthalmology, SDC has unparalleled experience in designing, building and analyzing ophthalmic clinical trials.

From Phase 1 to regulatory submission, SDC’s robust ophthalmic experience is The Right Fit For You.

Ophthalmology Experience:

Extensive Ophthalmology experience across the SDC project Teams

All phases of ophthalmic drug development:

Pilot, pivotal, and post-market device and diagnostic trials, including adaptive trial designs and pooled analysis for data submission

30+ Ophthalmology Product Approvals 

Frequent interaction with regulatory agencies

Supported development of CDISC standards for ophthalmology


30+ Product Approvals and Counting


Supporting the Next Generation of Cancer Therapy Through Thoughtful Guidance

Neurology & CNS

Thoughtful Collaboration with Your Team to Guide Your Development Strategy

Ophthalmic Indications

AMD: Wet & Dry
Atopic Keratoconjunctivitis
Bacterial Corneal Ulcers
Conjunctivitis: Allergic, Bacterial, Viral
Contact Lens
Contact Lens Solution
Corneal Deposit
Corneal Incision Sealant
Diabetic Macular Edema (DME)
Diabetic Retinopathy
Dry Eye

Glaucoma: Drug, Device
Impaired Dark Adaptation
Inflammation: Anterior/Posterior Chamber, Post-Operative
Inherited Retinal Disease
Intraocular Lens: Aspheric, Refractive
Leber’s Congenital Amaurosis (LCA)
Lid Scrub
Meibomian Gland Dysfunction
Neurotrophic Keratopathy

Ocular & Systemic Safety
Ocular Redness
Optical Coherence Tomography Device
Pediatric Cataract
Retinal Disease
Retinal Vein Occlusion
Retinitis Pigmentosa
Specular Microscope
Spheric IOL
Uveitis: Anterior, Posterior
Vitreal Detachment
X-linked Retinoschisis (XLRS)

Case Studies

SDC Optimizes Focus on Tech-Enabled Biometric Services

Phoenix, AZ  – Statistics & Data Corporation (SDC), a global leader in life sciences biometrics services and technology solutions, announces a strategic decision to enhance focus and efficiency by transitioning its ophthalmic biometric division to its partner Ora,...

read more